RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-11.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$696M
AUM Growth
+$696M
(-25%)
Cap. Flow
-$44.9M
Cap. Flow
% of AUM
-6.45%
Top 10 Holdings %
Top 10 Hldgs %
54.99%
Holding
75
New
17
Increased
7
Reduced
15
Closed
28
Top Buys
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
$22.7M |
| 2 |
Neurogene
NGNE
|
$21.6M |
| 3 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$20M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$19.3M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$12.6M |
Top Sells
| 1 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$24.1M |
| 2 |
MDCO
Medicines Co
MDCO
|
$20.2M |
| 3 |
Dynavax Technologies
DVAX
|
$17.9M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$16.1M |
| 5 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$14.9M |
Sector Composition
| 1 | Healthcare | 85.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
1
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $81.1M | 11.64% | 11,733,815 +1,787,818 | +18% | +$12.4M |
|
|
SIOX
2
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $64.6M | 9.28% | 5,000,000 | – | – |
|
|
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
| $48.7M | 6.99% | 2,551,193 -151,900 | -6% | -$2.9M |
|
4
Collegium Pharmaceutical
COLL
$1.22B
| $34.3M | 4.93% | 1,553,175 +7,765 | +0.5% | +$172K |
|
5
TG Therapeutics
TGTX
$4.65B
| $31.5M | 4.52% | 3,124,480 -177,733 | -5% | -$1.79M |
|
|
RGLS
6
DELISTED
Regulus Therapeutics
RGLS
| $26.4M | 3.79% | 4,039,823 +249,347 | +7% | +$1.63M |
|
7
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $26.2M | 3.76% | 1,305,020 -75,300 | -5% | -$1.51M |
|
8
Ascendis Pharma
ASND
$11.8B
| $25.9M | 3.71% | 1,461,268 -451,885 | -24% | -$8M |
|
|
ZGNX
9
DELISTED
Zogenix, Inc.
ZGNX
| $22.7M | 3.26% | +1,679,500 | New | +$22.7M |
|
|
10
Neurogene
NGNE
$264M
| $21.6M | 3.1% | +1,532,151 | New | +$21.6M |
|
11
Protara Therapeutics
TARA
$120M
| $21M | 3.01% | 1,506,872 | – | – |
|
|
AIMT
12
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $20M | 2.87% | +790,200 | New | +$20M |
|
|
DRNA
13
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $19.9M | 2.86% | 2,428,571 | – | – |
|
|
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $19.3M | 2.77% | +457,142 | New | +$19.3M |
|
|
BPMC
15
DELISTED
Blueprint Medicines
BPMC
| $18.7M | 2.69% | 878,348 | – | – |
|
16
Ardelyx
ARDX
$1.53B
| $18.4M | 2.64% | 1,064,013 -655,932 | -38% | -$11.3M |
|
17
Cidara Therapeutics
CDTX
$1.66B
| $15M | 2.16% | 1,180,570 +39,237 | +3% | +$499K |
|
|
BLUE
18
DELISTED
bluebird bio
BLUE
| $14.3M | 2.06% | 167,367 +57,984 | +53% | +$4.96M |
|
|
19
BioCryst Pharmaceuticals
BCRX
$1.74B
| $13.6M | 1.96% | 1,196,603 -1,408,758 | -54% | -$16.1M |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.6M | 1.81% | +314,349 | New | +$12.6M |
|
|
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $12.4M | 1.78% | +604,982 | New | +$12.4M |
|
22
Arcturus Therapeutics
ARCT
$462M
| $11.1M | 1.59% | 1,832,911 +307,017 | +20% | +$1.85M |
|
23
TherapeuticsMD
TXMD
$12.8M
| $8.9M | 1.28% | 1,518,460 -161,935 | -10% | -$949K |
|
|
NDRM
24
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $8.79M | 1.26% | +425,000 | New | +$8.79M |
|
25
Natera
NTRA
$23.1B
| $8.5M | 1.22% | +783,521 | New | +$8.5M |
|